

Gamma Delta T Cell Cancer Therapy Market & Clinical Trials Forecast 2028

<https://marketpublishers.com/r/G30FE155861BEN.html>

Date: April 2022

Pages: 180

Price: US\$ 2,800.00 (Single User License)

ID: G30FE155861BEN

Abstracts

Please note: extra shipping charges are applied when purchasing Hard Copy License depending on the location.

“Gamma Delta T Cell Cancer Therapy Market & Clinical Trials Forecast 2028” Report Highlights:

Commercialization Market Potential After Market Launch: > USD 4 Billion

Insight on Key Drugs In Research & Development

Global Gamma Delta T Cell Cancer Therapy Clinical Trials Insight

Gamma Delta T Cell Cancer Therapy In clinical Trials: > 15 Therapies

Gamma Delta T Cell Cancer Therapy Market Opportunity By Cancer Type

Adopted Approaches for Gamma Delta T Cell Therapy

The introduction of T cell based immunotherapy has greatly revolutionized the paradigm of cancer treatment. The progress in clinical research and innovation has led to the identification of small subsets of T cells classified as gamma delta T cells. Gamma delta T cells are the minor subsets of T cells which constitutes only about 1% to 5% of T cell population. Their unique biology and conferred advantages over conventional T cells has enabled the researchers to utilize these novel cells as promising candidate for adoptive immunotherapy. Since its identification, scientists have harnessed the potential of gamma delta T cells in the management of several cancers.

The gamma delta T cell therapy represents one of the most promising T cell therapies in clinical development which can be suggested by the rapid research and development activities among the pharmaceutical companies. The major companies in the market are presenting promising preclinical and clinical data of gamma delta T cell therapies. For instance in 2022, In8bio provided an update on ongoing phase-I clinical trial of INB-200. The novel gamma delta T cell product has shown manageable safety profile and promising progression free survival and overall survival rate. The encouraging data from clinical trial suggests the promising future of gamma delta T cell therapy in the management of cancer.

Apart from cancer, researchers are also expanding the role of gamma delta T cell therapy in the management of other diseases such as HIV, COVID-19, and other viral infections. Recently, Enochian Biosciences announced that US FDA has accepted a pre-investigational new drug request for a cell therapy treatment which combines autologous natural killer and gamma delta T-cells. Furthermore, several preclinical studies also indicate an innate involvement of gamma delta T cells in viral infections. The coming years will witness translation of these investigations in clinical trials, which will further propel the growth of market.

The rising investment from the pharmaceutical giants have led to the development of strong clinical pipeline of gamma delta T cell therapy products. The key players operating in the market are Acopiedia, Takeda Pharma, Lava Therapeutics, TC Biopharma, Cytomed Therapeutics, Gamma delta Therapeutics and Adapate Therapeutics. The major drugs in the clinical pipeline include INB-200, LAVA-051, ADI-001, TCB-007, ACE-1813, KB-PD1, and several others. Apart from this, several pharmaceutical giants have also entered into collaboration, mergers, or other alliances to maintain their position in the market. In January 2022, Takeda Pharmaceutical announced the exercise of its option to acquire Adapate Therapeutics. Through this acquisition, Takeda will obtain Adapate antibody based gamma delta T-cell engager platform including pre-clinical candidate and discovery pipeline programs.

US is currently dominating the global initiatives in development of gamma delta T cell therapy driven by large number of ongoing clinical trials, presence of key players in the region, and increasing initiatives from various stake holders in the industry . Apart from this, US FDA is also granting orphan drug designation to gamma T cell therapies which provides several financial and non-financial incentives to boost the drug development process. For instance in 2021, US FDA has granted orphan drug designation to two gamma delta T cell therapies including GDX012 for acute myeloid leukemia and

LAVA-051 for chronic lymphocytic leukemia.

As per our report findings, the global gamma delta T-cell therapy market is expected to surpass US\$ 4 Million by 2028. The rise in cancer rates and the subsequent unavailability of effectively curing drugs will propel the growth of the market for coming years. In addition, new product launches, continuous investment by pharmaceutical companies, and increasing government initiatives will also contribute in growth of market. The report provides comprehensive analysis on the ongoing clinical trials in gamma delta T cell therapy. By analyzing the market dynamics, the future market opportunity of gamma delta T cell therapy in various cancers is also forecasted.

Contents

1. INTRODUCTION TO GAMMA DELTA T CELL THERAPY

- 1.1 Emerging Role of T Cell Based Immunotherapies
- 1.2 Overview to Gamma Delta T Cell Therapy

2. GAMMA DELTA T CELL THERAPY VS. CONVENTIONAL THERAPIES

- 2.1 Gamma Delta T Cell Therapy Vs. CAR T Cell Therapy
- 2.2 Gamma Delta T Cell Therapy Vs. Tumor Infiltrating Lymphocyte Therapy
- 2.3 Gamma Delta T Cell Therapy Vs. Immune Checkpoint Inhibitors
- 2.4 Gamma Delta T Cell Therapy Vs. Monoclonal Antibodies
- 2.5 Gamma Delta T Cell Therapy Vs. Others

3. ROLE OF GAMMA DELTA T CELLS IN CANCER

- 3.1 Gamma Delta T Cells in Cancer Progression
- 3.2 Anti Tumor Activity of Gamma Delta T Cells

4. ADOPTED APPROACHES FOR GAMMA DELTA T CELL THERAPY

- 4.1 Gamma Delta T Cell as Bispecific Antibodies
- 4.2 CAR Gamma Delta T Cells

5. GAMMA DELTA T CELL THERAPY: KEY DRUGS IN RESEARCH & DEVELOPMENT

6. GLOBAL GAMMA DELTA T CELL CANCER THERAPY CLINICAL PIPELINE OVERVIEW

- 6.1 By Company
- 6.2 By Country
- 6.3 By Indication
- 6.4 By Phase

7. GLOBAL GAMMA DELTA T CELL CANCER THERAPY CLINICAL TRIALS INSIGHT BY COMPANY, INDICATION & CLINICAL PHASE

- 7.1 Research
- 7.2 Preclinical
- 7.3 Clinical
- 7.4 Phase-I
- 7.5 Phase-I/II

8. GAMMA DELTA T CELL THERAPY IN LEUKEMIA

- 8.1 Role of Gamma Delta T Cells in Leukemia
- 8.2 Ongoing Clinical Research in Acute Leukemia
- 8.3 Clinical Trials in Chronic Lymphocytic Leukemia
- 8.4 Future Market Opportunity of Gamma Delta T Cells in Leukemia

9. GAMMA DELTA T CELL THERAPY IN LUNG CANCER

- 9.1 Overview
- 9.2 Ongoing Research & Development
- 9.3 Future Market Opportunity of Gamma Delta T Cell Therapy in Lung Cancer

10. GAMMA DELTA T CELLS IN BREAST CANCER

- 10.1 Overview
- 10.2 Ongoing Research & Development in Breast Cancer
- 10.3 Future Market Opportunity of Gamma Delta T Cell Therapy in Breast Cancer

11. GAMMA DELTA T CELLS IN COLORECTAL CANCER

- 11.1 Function of Gamma Delta T Cells in Colorectal Cancer
- 11.2 Ongoing Clinical Trials in Colorectal Cancer
- 11.3 Future Market Potential of Gamma Delta T Cell Therapy in Colorectal Cancer

12. GAMMA DELTA T CELLS IN PANCREATIC CANCER

- 12.1 Overview
- 12.2 Ongoing Research & Development in Pancreatic Cancer
- 12.3 Future Market Potential of Gamma Delta Therapy in Pancreatic Cancer

13. CURRENT CLINICAL RESEARCH IN OTHER CANCERS

- 13.1 Ongoing Clinical Trials in Neuroblastoma
- 13.2 Ongoing Clinical Trials in Glioblastoma
- 13.3 Ongoing Research & Development in Head & Neck Cancer

14. GAMMA DELTA T CELL THERAPY MARKET OVERVIEW

- 14.1 Current Market Scenario
- 14.2 Market Potential of Gamma Delta T Cell Therapy Market

15. GAMMA DELTA T CELL THERAPY MARKET DYNAMICS

- 15.1 Gamma Delta T Cell Therapy Market: Favorable Parameters
- 15.2 Gamma Delta T Cell Therapy Market: Challenges

16. GAMMA DELTA T CELL THERAPY FUTURE PROSPECTS

17. COMPETITIVE LANDSCAPE

- 17.1 Acepodia
- 17.2 Adaptate Therapeutics
- 17.3 Adicet
- 17.4 Cytomed Therapeutics
- 17.5 Gadeta
- 17.6 GammaDelta Therapeutics
- 17.7 IN8bio
- 17.8 Kiromic Biopharma
- 17.9 Lava Therapeutics
- 17.10 Takeda Pharmaceuticals
- 17.11 TC Biopharm

List Of Figures

LIST OF FIGURES

- Figure 1-1: History of T cell Based Immunotherapy
- Figure 1-2: Gamma Delta T cell Therapy
- Figure 1-3: Stimulants of Gamma Delta T Cells
- Figure 2-1: Limitation of CAR T Cell Therapy
- Figure 2-2: Limitations of TIL
- Figure 2-3: Limitations of Monoclonal Antibodies
- Figure 2-4: Drawback of Chemotherapeutic Drugs
- Figure 3-1: Pro-Tumor Role of Gamma Delta T Cells
- Figure 3-2: Antigen Presentation Functions of Gamma Delta T-Cells
- Figure 3-3: Anti-Tumor Activity of Gamma Delta T-Cells
- Figure 4-1: Gamma Delta T Cell Bispecific Antibodies – Mechanism of Action
- Figure 4-2: Functional Advantages of ?? T Cells for CAR T Cancer Therapy
- Figure 4-3: CAR ?? T Cells – Mechanism of Action
- Figure 5-1: ADI-001 – Initiation & Completion Year of Phase-I Clinical Trial
- Figure 5-2: LAVA-051 – Initiation & Completion Year of Phase-I/II Clinical Trial
- Figure 5-3: DRI Cell Therapy – Initiation & Completion Year of Phase-I Clinical Trial
- Figure 5-4: Adoptive Cell Therapy – Initiation & Completion Year of Phase-I Clinical Trial
- Figure 5-5: GDX012 – Initiation & Completion Year of Phase-I Clinical Trial
- Figure 5-6: GDT002 – Initiation & Completion Year of Phase-I Clinical Trial
- Figure 6-1: Global - Gamma Delta T Cell Cancer Therapy in Clinical Pipeline by Company, 2022 till 2028
- Figure 6-2: Global - Gamma Delta T Cell Cancer Therapy in Clinical Pipeline by Country, 2022 till 2028
- Figure 6-3: Global - Gamma Delta T Cell Cancer Therapy in Clinical Pipeline by Indication, 2022 till 2028
- Figure 6-4: Global Gamma Delta T Cell Cancer Therapy in Clinical Pipeline by Phase, 2022 till 2028
- Figure 8-1: Global – Leukemia Incidences & Mortality (Million), 2020 & 2040
- Figure 8-2: Benefits of Gamma Delta T Cells in Leukemia
- Figure 8-3: Mechanism of Action of V?9/CD123 Bispecific Antibody
- Figure 8-4: Global – Estimated Leukemia Cancer Cases, 2021-2028
- Figure 8-5: US – Estimated Leukemia Cancer Cases, 2021-2028
- Figure 8-6: Europe – Estimated Leukemia Cancer Cases, 2021-2028
- Figure 8-7: China – Estimated Leukemia Cancer Cases, 2021-2028
- Figure 8-8: Japan – Estimated Leukemia Cancer Cases, 2021-2028

Figure 9-1: Global – Lung Cancer Incidences & Mortality (Million), 2020 & 2040

Figure 9-2: Role of Gamma Delta T Cells in Lung Cancer

Figure 9-3: Global – Estimated Lung Cancer Cases, 2021-2028

Figure 9-4: US – Estimated Lung Cancer Cases, 2021-2028

Figure 9-5: Europe – Estimated Lung Cancer Cases, 2021-2028

Figure 9-6: China – Estimated Lung Cancer Cases, 2021-2028

Figure 9-7: Japan – Estimated Lung Cancer Cases, 2021-2028

Figure 10-1: Global – Breast Cancer Incidences (Million), 2020 & 2040

Figure 10-2: Global – Breast Cancer Mortality (Million), 2020 & 2040

Figure 10-3: Global – Estimated Breast Cancer Cases, 2021-2028

Figure 10-4: US – Estimated Breast Cancer Cases, 2021-2028

Figure 10-5: Europe – Estimated Breast Cancer Cases, 2021-2028

Figure 10-6: China – Estimated Breast Cancer Cases, 2021-2028

Figure 10-7: Japan – Estimated Breast Cancer Cases, 2021-2028

Figure 11-1: Role of Gamma Delta T Cells in Colorectal Cancer

Figure 11-2: Mechanism Underlying B7-H3 Regulating ?? T Cells Killing Colon Cancer Cells

Figure 11-3: Global – Estimated Colorectal Cancer Cases, 2021-2028

Figure 11-4: US – Estimated Colorectal Cancer Cases, 2021-2028

Figure 11-5: Europe – Estimated Colorectal Cancer Cases, 2021-2028

Figure 11-6: China – Estimated Colorectal Cancer Cases, 2021-2028

Figure 11-7: Japan – Estimated Colorectal Cancer Cases, 2021-2028

Figure 12-1: Global – Pancreatic Cancer Incidences, 2020 & 2040

Figure 12-2: Global – Pancreatic Cancer Mortality, 2020 & 2040

Figure 12-3: Role of Gamma Delta T Cells in Pancreatic Cancer Progression

Figure 12-4: Global – Estimated Pancreatic Cancer Cases, 2021-2028

Figure 12-5: US – Estimated Pancreatic Cancer Cases, 2021-2028

Figure 12-6: Europe – Estimated Pancreatic Cancer Cases, 2021-2028

Figure 12-7: China – Estimated Pancreatic Cancer Cases, 2021-2028

Figure 12-8: Japan – Estimated Pancreatic Cancer Cases, 2021-2028

Figure 14-1: Global - Cell Therapy Market (US\$ Billion), 2020 - 2028

Figure 14-2: Global – Gamma Delta T Cell Therapy Market Opportunity by 1% of Total Cell Therapy Market (US\$ Billion), 2022-2028

Figure 14-3: Global – Gamma Delta T Cell Therapy Market Opportunity by 2% of Total Cell Therapy Market (US\$ Billion), 2022-2028

Figure 14-4: Global – Gamma Delta T Cell Therapy Market Opportunity by 3% of Total Cell Therapy Market (US\$ Billion), 2022-2028

Figure 14-5: Global – Gamma Delta T Cell Therapy Market Opportunity by 4% of Total Cell Therapy Market (US\$ Billion), 2022-2028

Figure 14-6: Global – Gamma Delta T Cell Therapy Market Opportunity by 5% of Total Cell Therapy Market (US\$ Billion), 2022-2028

Figure 14-7: Global – Gamma Delta T Cell Therapy Market Opportunity by 6% of Total Cell Therapy Market (US\$ Billion), 2022-2028

Figure 14-8: Global – Gamma Delta T Cell Therapy Market Opportunity by 7% of Total Cell Therapy Market (US\$ Billion), 2022-2028

Figure 14-9: Global – Gamma Delta T Cell Therapy Market Opportunity by 8% of Total Cell Therapy Market (US\$ Billion), 2022-2028

Figure 14-10: Global – Gamma Delta T Cell Therapy Market Opportunity by 9% of Total Cell Therapy Market (US\$ Billion), 2022-2028

Figure 14-11: Global – Gamma Delta T Cell Therapy Market Opportunity by 10% of Total Cell Therapy Market (US\$ Billion), 2022-2028

Figure 15-1: Global – Cancer Incidences & Mortality Rates (Billion), 2020 & 2040

Figure 15-2: Gamma Delta T Cells Favorable Market Parameters

Figure 15-3: Stages of Drug Development

List Of Tables

LIST OF TABLES

Table 8-1: Global – Estimated Adoption Rate of Gamma Delta T Cell in Leukemia, 2022-2028

Table 8-2: US – Estimated Adoption Rate of Gamma Delta T Cell in Leukemia, 2022-2028

Table 8-3: Europe – Estimated Adoption Rate of Gamma Delta T Cell in Leukemia, 2022-2028

Table 8-4: China – Estimated Adoption Rate of Gamma Delta T Cell in Leukemia, 2022-2028

Table 8-5: Japan – Estimated Adoption Rate of Gamma Delta T Cell in Leukemia, 2022-2028

Table 9-1: Global – Estimated Adoption Rate of Gamma Delta T Cell in Lung Cancer, 2022-2028

Table 9-2: US – Estimated Adoption Rate of Gamma Delta T Cell in Lung Cancer, 2022-2028

Table 9-3: Europe – Estimated Adoption Rate of Gamma Delta T Cell in Lung Cancer, 2022-2028

Table 9-4: China – Estimated Adoption Rate of Gamma Delta T Cell in Lung Cancer, 2022-2028

Table 9-5: Japan – Estimated Adoption Rate of Gamma Delta T Cell in Lung Cancer, 2022-2028

Table 10-1: Global – Estimated Adoption Rate of Gamma Delta T Cell in Breast Cancer, 2022-2028

Table 10-2: US – Estimated Adoption Rate of Gamma Delta T Cell in Breast Cancer, 2022-2028

Table 10-3: Europe – Estimated Adoption Rate of Gamma Delta T Cell in Breast Cancer, 2022-2028

Table 10-4: China – Estimated Adoption Rate of Gamma Delta T Cell in Breast Cancer, 2022-2028

Table 10-5: Japan – Estimated Adoption Rate of Gamma Delta T Cell in Breast Cancer, 2022-2028

Table 11-1: Global – Estimated Adoption Rate of Gamma Delta T Cell in Colorectal Cancer, 2022-2028

Table 11-2: US – Estimated Adoption Rate of Gamma Delta T Cell in Colorectal Cancer, 2022-2028

Table 11-3: Europe – Estimated Adoption Rate of Gamma Delta T Cell in Colorectal

Cancer, 2022-2028

Table 11-4: China – Estimated Adoption Rate of Gamma Delta T Cell in Colorectal Cancer, 2022-2028

Table 11-5: Japan – Estimated Adoption Rate of Gamma Delta T Cell in Colorectal Cancer, 2022-2028

Table 12-1: Global – Estimated Adoption Rate of Gamma Delta T Cell in Pancreatic Cancer, 2022-2028

Table 12-2: US – Estimated Adoption Rate of Gamma Delta T Cell in Pancreatic Cancer, 2022-2028

Table 12-3: Europe – Estimated Adoption Rate of Gamma Delta T Cell in Pancreatic Cancer, 2022-2028

Table 12-4: China – Estimated Adoption Rate of Gamma Delta T Cell in Pancreatic Cancer, 2022-2028

Table 12-5: Japan – Estimated Adoption Rate of Gamma Delta T Cell in Pancreatic Cancer, 2022-2028

I would like to order

Product name: Gamma Delta T Cell Cancer Therapy Market & Clinical Trials Forecast 2028

Product link: <https://marketpublishers.com/r/G30FE155861BEN.html>

Price: US\$ 2,800.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/G30FE155861BEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970